What type of drug is Copiktra?
Copiktra (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant B-cells (cancerous white blood cells).
Copiktra is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies, when they did not work or are no longer working.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are both cancers that affect lymphocytes, a type of white blood cell that plays an important role in the immune system.
CLL and SLL are essentially the same disease, with the only difference being the location where the cancer primarily occurs.
- CLL - most of the cancer cells are located in the bloodstream and the bone marrow (although lymph nodes and spleen are often involved)
- SLL - most of the cancer cells are located in the lymph nodes.
Copiktra also initially received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The approval for FL was based on overall response rate, with continued approval contingent upon verification of clinical benefit in confirmatory trials.
Secura Bio, Inc. announced the voluntarily withdrawal of follicular lymphoma indication for Copiktra in December 2021.
Read next
What is the success rate of Breyanzi?
Everyone will respond differently to Breyanzi (lisocabtagene maraleucel), and the success rate for someone else may be different than for you. Based on clinical trial data, the complete response rate in patients taking Breyanzi is around 20% to 73%, depending on the condition being treated. Continue reading
What is the survival rate of Kymriah?
Studies are ongoing to monitor the survival rate of patients who received Kymriah (tisagenlecleucel) as a cancer treatment. Currently, the available data shows the survival rate is 87.7% for patients with relapsed or refractory follicular lymphoma at 24 months after the Kymriah infusion, and 43.6% for patients with aggressive B-cell non-Hodgkin’s lymphoma. The 5-year survival rate for patients with advanced B-cell advanced B-cell acute lymphoblastic leukemia is 55%. Continue reading
What's the difference between Kymriah and Yescarta?
Kymriah and Yescarta are two cell-based gene therapies. A few differences between the two medications include who and what they are FDA approved for, their dosage, and which companies make them. Continue reading
Related medical questions
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- What is the difference between Truxima and Rituxan?
- Does Truxima make you gain weight?
- What are the names of the BTK inhibitors?
- What is the cost of Kymriah?
- What is Zydelig used for and how does it work?
- What is the success rate of Epkinly?
- What is the difference between Rituxan and Rituxan Hycela?
- How is Rituxan Hycela administered?
- What type of drug is Yescarta (axicabtagene ciloleucel)?
- How will I feel after a Rituxan infusion?
- How long does it take for Rituxan to work?
- How long does it take for Jaypirca to work?
- How does the drug Rituxan work?
- Is Venclexta (venetoclax) chemotherapy?
- How do you prepare for a Rituxan infusion?
- What causes infusion reactions to rituximab?
- Does ibrutinib cause hair loss?
- How effective is Venclexta?
- How long do you take Venclexta for?
- Is Truxima a chemotherapy drug?
- How is Arzerra administered and how long to work?
- Is Zydelig a chemotherapy drug?
- What is Arzerra used for and how does it work?
- How is Bendeka different to Treanda?
- Who makes Leukeran, and where is it made?
- How does Venclexta work?
Drug information
Related support groups
- Duvelisib (1 questions, 3 members)
- Copiktra (1 questions, 3 members)
- Follicular Lymphoma (15 questions, 15 members)
- Chronic Lymphocytic Leukemia (CLL) (26 questions, 57 members)